Home/Filings/4/0001104659-25-099647
4//SEC Filing

Martin John Alexander 4

Accession 0001104659-25-099647

CIK 0001633932other

Filed

Oct 14, 8:00 PM ET

Accepted

Oct 15, 11:57 AM ET

Size

5.4 KB

Accession

0001104659-25-099647

Insider Transaction Report

Form 4
Period: 2025-10-09
Transactions
  • Disposition to Issuer

    Common Shares

    2025-10-0914,2990 total
Footnotes (1)
  • [F1]On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

Issuer

ESSA Pharma Inc.

CIK 0001633932

Entity typeother

Related Parties

1
  • filerCIK 0001504224

Filing Metadata

Form type
4
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 11:57 AM ET
Size
5.4 KB